In short
More than 260 people with Parkinson's had been dosed in Zhittya's research studies. The brain blood-flow imaging work at Washington University in St. Louis stayed open to more participants. Dr. Jack Jacobs presented the FGF-1 research at RAADfest 2026.
September's update began with RAADFest, a conference in Scottsdale, Arizona, where Dr. Jack Jacobs presented Zhittya's research. Several participants with Parkinson's came to see the team there.
The update described meeting the one participant in Zhittya's research study on cerebellar atrophy, a wasting of the cerebellum, a part of the brain. The update said the condition is estimated to affect around 100,000 Americans. He told the team he was feeling better and performing better.
Working with independent physicians
The update announced a Physicians and Wellness Clinics Network. It said that as Parkinson's data came in over four years, physicians in private practice had studied it and asked how they could work with Zhittya.
By September, the update said, more than 260 people with Parkinson's had taken part. It said many had reported back to their regular doctors, and that doctors in private practice tended to show more interest in those reports than doctors employed by large organizations.
The update gave the example of one physician who now gives short talks at his clinic about the research. The chief executive wrote that he had reminded this physician that FGF-1 is not approved by the FDA, that approval could take 5 to 20 years and may never come at all, and that he could not prescribe it.
Wellness clinics were also part of the plan. The company hopes about 1,700 independent physicians and clinics will join, and it is developing plans to expand the program in 2027.
Memory and cluster headaches
In describing a conversation about dementia, the chief executive wrote that Zhittya had dosed about seven people with dementia and about 30 people with Parkinson's who also had memory problems. He said the team had seen positive signs.
The update also took up cluster headaches, a rare and extremely painful condition that it said affects roughly 130,000 to 170,000 Americans. An AI-assisted search found no research at all on FGF-1 and cluster headaches.
Sergiy Montano then asked which brain mechanisms are suspected of contributing to the condition. The search named four, and for each one it answered that FGF-1 could have an influence. He wrote a brief paper on the idea.
The update was clear that the team does not know whether FGF-1 can help with cluster headaches. It hoped to dose a first participant within 60 days.
It also said that more than 400 people had now received FGF-1 through the nose.
General status
The update said the research on degenerative brain disorders, including Parkinson's, stroke recovery, dementia and traumatic brain injury, was continuing. It said reports of improvement continued and that the September cohort, or group of participants, could be the largest so far.
The team was preparing a study plan on chronic pain to submit to an Institutional Review Board, a committee that reviews research involving people. Zhittya was making more FGF-1 each month than ever before and was looking to double its capacity again in 2027.
The brain imaging study at Washington University in St. Louis was continuing.
This summary covers the Parkinson's research in the September 2026 update. The complete update, including the other topics it covered, is below.
Read the complete September 2026 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.